Adaptimmune reports progress on GSK-partnered immune-oncology candidate
This article was originally published in Scrip
Adaptimmune, the UK biotech company which recently raised a $104m series A financing round from US investors, has released interim clinical data from a pilot trial of its T-cell therapy targeting the NY-ESO-1 antigen, a program partnered with GlaxoSmithKline, in the treatment of synovial sarcoma.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.